

Presentation at The First Chinese Symposium of Thrombosis and Haemostasis in Association with the ISTH Congress

Lee's Pharm is pleased to announce its support as a silver sponsorship of the First Chinese Symposium of Thrombosis and Haemostasis in association with the ISTH Congress which is being held at St. Michael's Hospital in Toronto, Ontario. This exciting one day event, endorsed by the International Society on Thrombosis and Haemostasis (ISTH) provides participants with an opportunity to learn more about ongoing research in mechanisms, prevention, diagnosis and treatment of thrombotic and bleeding disorders.

On 19th June 2015, Dr. Benjamin Li, CEO of the Group made a presentation at the symposium to provide an overview of Anfibatide (Title: Anfibatide, a first-in-class anti-platelet drug targeted GPIIb/IIIa receptor: from discovery to clinical trial). "We are proud to sponsor this first year congress", said Dr. Benjamin Li. "This symposium has an interesting mix of presentations and topics and we are delighted to be a part of it".

About Anfibatide

Anfibatide is a new molecular entity discovered and developed by the Group. It is a first-in-class platelet IIb/IIIa receptors antagonist and is currently undergone phase II clinical study. Animal studies have shown that intravenous injection of Anfibatide effectively abolishes the cyclic flow reduction in canine model of unstable angina with much less prolongation of bleeding time than platelet 2b3a receptors antagonist. Both in vitro and in vivo studies of Anfibatide show a benign safety profile for the agent. During the phase I study in 2010, a total of 96 healthy volunteers were exposed to different doses of Anfibatide and no severe adverse event, including bleeding event, was detected. Intravenous administration of Anfibatide by either bolus or continual infusion elicits strong ex-vivo platelet inhibition in both healthy volunteers and non STEMI patients in dose depending manner. Phase IIa study in 90 non STEMI patients undergoing PCI procedure also demonstrates that Anfibatide does not increase bleeding tendency in combination with other anti-platelet drugs Aspirin and Clopidogrel. A phase IIb study in 259 STEMI patients undergoing PCI procedure is under preparation with endpoints to demonstrate not only safety, but also efficacy of Anfibatide.



Certificate of Attendance

Thank you for attending the *First Chinese Symposium of Thrombosis and Haemostasis 2015*
in St. Michael's Hospital Li Ka Shing Knowledge Institute, Toronto,
Ontario on June 19 2015.



Dr. Heyu Ni
Director for Hematology, Cancer and Immunological Diseases,
St. Michael's Hospital
Chair, Organizing Committee

